Jörg Debatin to chair the supervisory board of Hummingbird Diagnostics GmbH

Home  >>  News  >>  Jörg Debatin to chair the supervisory board of Hummingbird Diagnostics GmbH

Jörg Debatin to chair the supervisory board of Hummingbird Diagnostics GmbH

On October 9, 2018, Posted by , In News, With Comments Off on Jörg Debatin to chair the supervisory board of Hummingbird Diagnostics GmbH

International healthcare leader strengthens miRNA experts

Hummingbird Diagnostics GmbH announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect.

The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO.

He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds an Executive MBA from the University of St. Gallen.

As a renowned international healthcare leader, he has extensive academic, clinical, and entrepreneurial experience in the fields of medical diagnostics and disease management as well as the implementation of innovative technologies.Thus, Prof. Debatin ideally augments the wide-ranging expertise of the Hummingbird Supervisory Board. Leading scientists, industrial managers and experienced investors support the company in expanding its portfolio of products and applications. “At Hummingbird, we are delighted to have Jörg Debatin on board, a globally renowned healthcare leader,” says Jochen Kohlhaas, CEO of Hummingbird Diagnostics GmbH. „His longstanding experience is invaluable for our future corporate development. “

“I am very happy to support Hummingbird Diagnostics in navigating upcoming challenges,“ Prof. Debatin remarks. “Using blood-based biomarkers for measuring the immune responses to disease holds immense promise for screening, symptom-based diagnostics, disease-specific prognosis and monitoring of patient-centered therapies.”

Download the Press Release.

Comments are closed.